Hybrid Closed-Loop Therapy in Adults With Type 1 Diabetes and Above-Target HbA1c: A Real-world Observational Study
Author:
Crabtree Thomas S.J.12ORCID, Griffin Tomás P.34, Yap Yew W.5, Narendran Parth67ORCID, Gallen Geraldine8, Furlong Niall9, Cranston Iain10, Chakera Ali1112ORCID, Philbey Chris13, Karamat Muhammad Ali14, Saraf Sanjay15, Kamaruddin Shafie16, Gurnell Eleanor17, Chapman Alyson18, Hussain Sufyan1920ORCID, Elliott Jackie21, Leelarathna Lalantha18, Ryder Robert E.J.22ORCID, Hammond Peter13, Lumb Alistair2324, Choudhary Pratik34, Wilmot Emma G.12, Evans Mark, Gurnell Eleanor, Hartnell Sara, Davenport Katy, O’Reilly Iona, Brown Helen, Kamaruddin Shafie, Pickering Sharon, Abouglia Kamal, Wadham Claire, Rayman Gerry, Hussain Sufyan, Brackenridge Anna, Pender Siobhan, Atkinson Rosarie, Bahadur Melanie, Eid Hatem, Carling Janet, Oldfield Linzi, Philbey Christopher, Hammond Peter, Haywood Sean, Gallen Geraldine, Rodgers Helen, Lovie Kaylee, Whight Emma, Nobel-Bell Georgia, Harris Sophie, Cartwright Anne, Garnett Ian, Harvey Jennifer, McCulloch Frances, Yap Yew Wen, Weston Philip, Chapman Alyson, Findlow Lynne, Leelarathna Lalantha, Ohol Sheetal, Thabit Hood, Urwin Andrea, Cowlam Darron, Thomas Sonia, Hyland Emma, Yearsley Zoey, Schofield Johnathan, Soar Clare, Fenn Laura, Mendis Budd, Htike Zin Zin, Cheyne Elizabeth, Emsley Julie, Jones Elisabeth, Parfitt Vernon, Sawyer Lynn, Colosimo Santo, Apsara Shani, Mathara Diddhenipothage Dilrukshi, Lumb Alistar, Hards Katie, Edohen Florence, Beaden Sue, Cranston Iain, Taylor Julie, Skinner Lisa, Bawlchhim Zosanglura, Tuthill Bev, Cull Melissa Louise, Ryder Robert E.J., Mitchell Sarah, Rimell Jill, Foley Clare, Gianfrancesco Carla, Elliott Jackie, Butter Sally, Carrieri Giorgio, Douek Isy, King Rhodri, Lambert Paul, Lionetti Paula, Cardwell Janet, Furlong Niall, Keigan Suzanne, Milne Rachael, Wilkinson Philomena, Ashton-Cleary Siobhan, White Sarah, Anthony Karen, Ribul Mazzola Stefania, Sweeney Stephanie, Narendran Parth, Karamat Ali, Saraf Sanjay, Hudson Barbara, Li Manyee, Skelding Rebecca, Williams Lisa, Bartha Karen, Jesson Anna-Marie, Grandy Lynn, Brewer Deborah, Edwards Joanne, Sears Nicola, Shergil Manjit, Baldwin Andy, Crabtree Thomas, Van Heeswijk Isabelle, Langeland Linn, Taylor Nicola, Wilmot Emma, Owen Sarah, Taylor Rachel, Robinson Emma, Bakhit Mohammed, Redfern Amy, Kedge Cathy, Kotonya Christine, Hayat Haleema, Gerrard Katy, Pearson Nicci, Redfern Zara, Curtis Louise, Galea Alison, Weiss Melanie, Stacey Nikki, Partridge Helen, Choudhary Pratik, Griffin Tomás, Ackroyd Dawn, Turrell Liz, Chakera Ali J., Lambert Vicki, Suarez Alison, Kirby Jesina, Lloyd Nicola, Karathenasi Eleni, McKinnon Samantha, Levitt Mindy, Govindan Raj, Haskoll Becky, Saunders Simon, Kehinde Razak, Lee James, Galliford Thomas, Bickerton Alex, Hammond Ruth, Walker Ruth,
Affiliation:
1. 1Department of Diabetes and Endocrinology, Royal Derby Hospital, University Hospitals of Derby and Burton NHS Trusts, Derby, U.K. 2. 2School of Medicine, Faculty of Medicine and Health Sciences, University of Nottingham, Nottingham, U.K. 3. 3Leicester Diabetes Center, University Hospitals of Leicester, Leicester, U.K. 4. 4Diabetes Research Center, College of Health Sciences, University of Leicester, Leicester, U.K. 5. 5Department of Diabetes and Endocrinology, Aintree University Hospital, Liverpool University Hospital NHS Foundation Trust, Liverpool, U.K. 6. 6Department of Diabetes, The Queen Elizabeth Hospital, Birmingham, Birmingham, U.K. 7. 7The Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, U.K. 8. 8Kings College Hospital NHS Trust, London, U.K. 9. 9Diabetes Center, St. Helens Hospital, St. Helens and Knowsley Teaching Hospitals NHS Trust, Merseyside, U.K. 10. 10Academic Department of Endocrinology and Diabetes Portsmouth Hospitals University NHS Trust, Queen Alexandra Hospital, Portsmouth, U.K. 11. 11Department of Diabetes and Endocrinology, University Hospitals Sussex, Brighton, U.K. 12. 12Brighton and Sussex Medical School, Brighton, U.K. 13. 13Department of Diabetes and Endocrinology, Harrogate and District NHS Trust, Harrogate, U.K. 14. 14Department of Diabetes and Endocrinology, Heartlands Hospital, University Hospitals Birmingham NHS Foundation Trust, Birmingham, U.K. 15. 15Department of Diabetes and Endocrinology, Good Hope Hospital, University Hospitals Birmingham NHS Foundation Trust, Sutton Coldfield, U.K. 16. 16Department of Diabetes and Endocrinology, County Durham and Darlington Foundation Trust, Darlington, U.K. 17. 17Wolfson Diabetes and Endocrine Clinic, Cambridge University Hospitals NHS Trust, Cambridge, U.K. 18. 18Manchester University NHS Foundation Trust, Manchester Royal Infirmary, Manchester, U.K. 19. 19Department of Diabetes, School of Cardiovascular, Metabolic Medicine and Sciences, King’s College London, London, U.K. 20. 20Department of Diabetes and Endocrinology, Guy’s and St. Thomas’ NHS Foundation Trust, London, U.K. 21. 21Diabetes and Endocrine Center, Sheffield Teaching Hospitals, Department of Oncology and Metabolism, The University of Sheffield, Sheffield, U.K. 22. 22Department of Diabetes and Endocrinology, City Hospital, Sandwell and West Birmingham Hospitals NHS Trust, Birmingham, U.K. 23. 23Oxford Center for Diabetes Endocrinology and Metabolism, Oxford University Hospitals NHS Trust, Oxford, U.K. 24. 24National Institute for Health and Care Research, Oxford Biomedical Research Center, Oxford, U.K.
Abstract
OBJECTIVE
We explored longitudinal changes associated with switching to hybrid closed-loop (HCL) insulin delivery systems in adults with type 1 diabetes and elevated HbA1c levels despite the use of intermittently scanned continuous glucose monitoring (isCGM) and insulin pump therapy.
RESEARCH DESIGN AND METHODS
We undertook a pragmatic, preplanned observational study of participants included in the National Health Service England closed-loop pilot. Adults using isCGM and insulin pump across 31 diabetes centers in England with an HbA1c ≥8.5% who were willing to commence HCL therapy were included. Outcomes included change in HbA1c, sensor glucometrics, diabetes distress score, Gold score (hypoglycemia awareness), acute event rates, and user opinion of HCL.
RESULTS
In total, 570 HCL users were included (median age 40 [IQR 29–50] years, 67% female, and 85% White). Mean baseline HbA1c was 9.4 ± 0.9% (78.9 ± 9.1 mmol/mol) with a median follow-up of 5.1 (IQR 3.9–6.6) months. Of 520 users continuing HCL at follow-up, mean adjusted HbA1c reduced by 1.7% (95% CI 1.5, 1.8; P < 0.0001) (18.1 mmol/mol [95% CI 16.6, 19.6]; P < 0.0001). Time in range (70–180 mg/dL) increased from 34.2 to 61.9% (P < 0.001). Individuals with HbA1c of ≤58 mmol/mol rose from 0 to 39.4% (P < 0.0001), and those achieving ≥70% glucose time in range and <4% time below range increased from 0.8 to 28.2% (P < 0.0001). Almost all participants rated HCL therapy as having a positive impact on quality of life (94.7% [540 of 570]).
CONCLUSIONS
Use of HCL is associated with improvements in HbA1c, time in range, hypoglycemia, and diabetes-related distress and quality of life in people with type 1 diabetes in the real world.
Funder
Association of British Clinical Diabetologists
Publisher
American Diabetes Association
Subject
Advanced and Specialized Nursing,Endocrinology, Diabetes and Metabolism,Internal Medicine
Reference36 articles.
1. NHS Digital
. National Diabetes Audit Core report 1: care processes and treatment targets 2021-22, underlying data, 2023. Accessed 5 February 2023. Available from https://digital.nhs.uk/data-and-information/publications/statistical/national-diabetes-audit/nda-core-21-22/nda-core-21-22-data 2. Global incidence, prevalence, and mortality of type 1 diabetes in 2021 with projection to 2040: a modelling study;Gregory;Lancet Diabetes Endocrinol,2022 3. NHS Digital
. National Diabetes Insulin Pump Audit, 2017-18, 2018. Accessed 6 February 2023. Available from https://files.digital.nhs.uk/E0/030704/National%20Diabetes%20Insulin%20Pump%20Audit%202017-18%20Report%20v2.pdf 4. The impact of hypoglycaemia on quality of life outcomes among adults with type 1 diabetes: a systematic review;Chatwin;Diabetes Res Clin Pract,2021 5. UK’s Association of British Clinical Diabetologist’s Diabetes Technology Network (ABCD-DTN): best practice guide for hybrid closed-loop therapy;Griffin;Diabet Med,2023
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
|
|